These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Effect of thalidomide on tumor growth in mouse hepatoma H22 model].
    Author: Zhai Y, Lu ZJ.
    Journal: Ai Zheng; 2003 Dec; 22(12):1301-6. PubMed ID: 14693056.
    Abstract:
    BACKGROUND & OBJECTIVE: Thalidomide may have curative effect on tumor because of its function of anti-angiogenesis. The aim of this research was to observe the effect of thalidomide on tumor homograft growth in mouse H22 model and to investigate the mechanisms involved and its curative possibility to hepatoma. METHODS: BALB/c mice were inoculated subcutaneously with H22 cells. The first treatment group was injected intraperitoneal everyday with thalidomide 50 mg/kg from the day of inoculation and the second treatment group was injected from the fourth day of inoculation. The diameters of the tumors were measured everyday. On the twelfth day, the mice were sacrificed and the tumors were weighed. The microvessel densities of the tumors were measured by immunohistochemical staining with anti-CD31 monoclonal antibody; CD31 expression, apoptosis, and proliferation were analyzed by flow cytometry. Expression of vascular endothelial growth factor (VEGF) mRNA was examined by reverse transcription-polymerase chain reaction (RT-PCR). RESULTS: The tumor weight of the first treatment group (2.27+/-0.33 g) was decreased compared with that of control group (2.70+/-0.61 g) (P >0.05); the ratio of inhibition was 15.93%. The tumor weight of the second treatment group (3.32+/-0.47 g) was decreased compared with that of control group (3.42+/-0.60 g) (P >0.05); the ratio of inhibition was 2.92%. The microvessel count (48.40+/-12.90) and CD31 expression (5.59+/-0.75) of the first treatment group were significantly decreased (P< 0.05) in comparison with those of control groups (81.20+/-26.91,7.04+/-0.50) (P< 0.05). The microvessel count (46.4+/-9.71) and CD31 expression (7.29+/-0.48) of the second treatment group were not statistically significant (P >0.05) compared with those of control groups (74.0+/-32.69, 6.80+/-0.68) (P >0.05). The apoptosis indices of the two treatment groups (17.20+/-7.80,15.33+/-4.10) were significantly increased, compared with control groups (4.37+/-1.98,4.87+/-1.91) (P< 0.05), while there was no significant difference of VEGF mRNA expression between the two treatment groups and control groups (P >0.05). The relative quantities of VEGF mRNA of the two treatment groups were 0.50+/-0.13 and 0.51+/-0.06 (control groups:0.48+/-0.11 and 0.64+/-0.11) (P >0.05), respectively. CONCLUSION: Thalidomide can significantly induce apoptosis and inhibit angiogenesis in mouse H22 model when it is used at the beginning of carcinogenesis, but it has no obvious anti-angiogenic efficacy on the grown tumor. Thalidomide cannot inhibit VEGF mRNA expression of grafted H22 tumor in mouse.
    [Abstract] [Full Text] [Related] [New Search]